By Caroline Humer NEW YORK (Reuters) – Valeant Pharmaceuticals International said on Sunday that Chief Executive Officer Michael Pearson would return from medical leave effective immediately, and it postponed the release of fourth-quarter results planned for Monday. Valeant was under pressure for its drug price increases when it said in late December that Pearson had been hospitalized for severe pneumonia. Weeks later, the company appointed board member and former Chief Financial Officer Howard Schiller as interim CEO, saying Pearson remained unwell.
Read more:
Valeant CEO Pearson to return effective immediately, results delayed
